STOCK TITAN

Immunic Inc - IMUX STOCK NEWS

Welcome to our dedicated news page for Immunic (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunic's position in the market.

Rhea-AI Summary
IMUX: Positive Interim Analysis from Phase 2 CALLIPER Trial Shows Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosis Population and All Subtypes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Immunic, Inc. (Nasdaq: IMUX) will release its Q3 financial results on November 14, 2023, before the opening of the U.S. financial markets. The webcast to discuss the results and provide a corporate update will be held at 8:00 am ET on the same day. Participants can register in advance on Immunic's website and will receive a confirmation email with the participation link or dial-in access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary
Biotech company Immunic, Inc. has received a Notice of Allowance from the USPTO for a patent application related to the treatment of Multiple Sclerosis with DHODH inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
Rhea-AI Summary
Biotech company Immunic, Inc. will present data from its phase 1b clinical trial of IMU-856, a small molecule modulator for celiac disease, at the AOECS conference. They will also attend BIO-Europe for partnering activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
Rhea-AI Summary
Immunic announces positive results from phase 2 trial of vidofludimus calcium in ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
-
Rhea-AI Summary
Immunic presents positive results from phase 1b clinical trial of IMU-856 for celiac disease at UEGW 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
-
Rhea-AI Summary
Immunic announces positive interim data from phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis (PMS)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.84%
Tags
-
Rhea-AI Summary
Immunic, Inc. announces participation in scientific conferences in October.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
Rhea-AI Summary
Immunic, Inc. to participate in industry and investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
Immunic Inc

Nasdaq:IMUX

IMUX Rankings

IMUX Stock Data

129.50M
49.38M
7.72%
58.06%
3.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Martinsried

About IMUX

immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu